Skip to main content

FDA recall, , Moderate risk

Roche Diagnostics Elecsys Anti-TSHR Immunoassay

The Elecsys Anti-TSHR immunoassay results vary by instrument platform and calibrator lot, which may lead to delayed or incorrect diagnosis.

What happened

Roche Diagnostics Operations, Inc., of Indianapolis, Indiana, began recalling the Elecsys Anti-TSHR immunoassay on November 21, 2025. The agency identified two issues: results vary by instrument platform and calibrator lot-to-lot variability. These issues may lead to delayed or incorrect diagnosis, as well as delay of treatment or incorrect treatment.

The product is a three-step competitive immunoassay with streptavidin-coated microparticles and electrochemiluminescence detection. The recall affects 1300 cassettes distributed nationwide in 20 states and Puerto Rico. The FDA added the recall to its Enforcement Report on January 2, 2026.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:

  1. A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
  2. Talk to your health care provider before you stop using it.

Is yours affected?

Affected if its UDI-DI and lot code are listed under that product.

A UDI-DI is the device identifier printed with the barcode on the device label.

  1. The Elecsys Anti-TSHR immunoassay

    UDI-DI
    • 08496633190
    • 08496609190
    Lot code
    • 840183
    • 874011
    • 840177

Recall details

Company began the recall
Company
Roche Diagnostics Operations, Inc.Indianapolis, Indiana
Risk

Moderate risk

Using it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
98103
Recall number
Z-1009-2026
Quantity recalled
1300 cassettes

All recalls from Roche Diagnostics Operations, Inc.

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. In FDA's weekly enforcement report

  4. Listed on Recall Canary

Summary by Recall Canary, written with AI · summary updated Oct 23, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)